Bone health in pediatric rheumatic disease

Current Opinion in Pediatrics

Volumn 17, Issue 6, 2005, Pages 703-708

  Rouster Stevens, Kelly A ^a   Klein Gitelman, Marisa S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bone density; Dual energy x ray absorptiometry; OPG (osteoprotegerin); Pediatric rheumatic disease; RANKL

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; INTERLEUKIN 1; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

BONE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE METABOLISM; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGEAL IRRITATION; ESOPHAGUS DISEASE; FRACTURE; HEALTH STATUS; HUMAN; HYPOCALCEMIA; INFLAMMATION; INJECTION SITE REACTION; INTERMETHOD COMPARISON; OSTEOPOROSIS; PEDIATRICS; PRIORITY JOURNAL; RADIATION EXPOSURE; RELIABILITY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; ULTRASOUND; VITAMIN SUPPLEMENTATION;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHILD; DENSITOMETRY, X-RAY; HUMANS; OSTEOPOROSIS; RHEUMATIC DISEASES; VITAMIN D;

EID: 28044470245     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000184048.13263.88     Document Type: Review

References (64)

1. Rabinovich CE. Bone metabolism in childhood rheumatic disease. Rheum Dis Clin N Am 2002; 28:655-667.
2. Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73:555-563.
3. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series. Geneva: WHO, 1994.
4. Bacon MC, White PH, Raiten DJ, et al. Nutritional status and growth in juvenile rheumatoid arthritis. Semin Arthritis Rheum 1990; 20:97-106.
5. Reed A, Haugen M, Pachman LM, Langman CB. 25-Hydroxyvitamin D therapy in children with active juvenile rheumatoid arthritis: short-term effects on serum osteocalcin levels and bone mineral density. J Pediatr 1991; 119:657-660.
6. Pepmueller PH, Cassidy JT, Allen Sh, Hillman LS. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 1996; 39:746-757.
7. Henderson CJ, Specker BL, Sierra RI, et al. Total-body bone mineral content in non-corticosteroid-treated postpubertal females with juvenile rheumatoid arthritis: frequency of osteopenia and contributing factors. Arthritis Rheum 2000; 43:531-540.
8. Stewart WA, Acott PD, Salisbury SR, Lang BA. Bone mineral density in juvenile dermatomyositis. Arthritis Rheum 2003; 48:2294-2298.
9. Alsufyani KA, Ortiz-Alvarez O, Cabral DA, et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005; 32:729-733. The majority of studies on bone mass in pediatric rheumatology have evaluated children with JIA, while this study demonstrates decreased bone density in SLE, JDM, and systemic vasculitis.
10. Brik R, Keidar Z, Schapira D, Israel O. Bone mineral density and turnover in children with systemic juvenile chronic arthritis. J Rheumatol 1998; 25:990-992.
11. Perez MD, Abrams SA, Loddeke L, et al. Effects of rheumatic disease and corticosteroid treatment on calcium metabolism and bone density in children assessed one year after diagnosis, using stable isotopes and dual energy x-ray absorptiometry. J Rheumatol 2000; 27:38-43.
12. Lien G, Selvaag, Flato B, et al. A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum 2005; 52:883-840. This study is unique compared to other reports of bone mass in pediatric rheumatology in that children with JIA were followed prospectively and found to have decreased bone mass compared to controls. This is one of few longitudinal studies evaluating bone mass in children.
13. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group. Lancet 1993; 341:972-975.
14. Elasser U, Wilkins B, Hesp R, et al. Bone rarefaction and crush fractures in juvenile chronic arthritis. Arch Dis Child 1982; 57:377-380.
15. Varonos S, Ansell BM, Reeve J. Vertebral collapse in juvenile chronic arhtritis: its relationship with glucocorticoid therapy. Calcif Tissue Int 1987; 41:75-78.
16. Murray KJ, Boyle RJ, Woo P. Pathological fractures and osteoporosis in a cohort of 103 systemic onset juvenile idiopathic arthritis patients. Arthritis Rheum 2000; 43:3119.
17. Lachman E. Osteoporosis: the potentialities and limitations of its radiologic diagnosis. Am J Radiol 1985; 4:712-717.
18. Gilsanz V. Bone density in children: a review of the available techniques and indications. Eur J Radiol 1998; 26:177-182.
19. Southard RN, Morris JD, Mahan JD, et al. Bone mass in healthy children: measurement with quantitative DXA. Radiology 1991; 179:735-738.
20. Lu PW, Briody JN, Ogle GD, et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994; 9:1451-1458.
21. Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr 2004; 144:253-257. The importance of monitoring Z-scores rather than T-scores in the interpretation of DXA is emphasized.
22. Molgaard C, Thomsen BL, Prentice A, et al. Whole body mineral content in healthy children and adolescents. Arch Dis Child 1997; 76:9-15.
23. Horlick M, Wang J, Pierson RN, Thornton JC. Prediction models for evaluation of total-body bone mass with dual-energy x-ray absorptiometry among children and adolescents. Pediatrics 2004; 114:e337-e345.
24. Wren TAL, Liu X, Pitukcheewanont P, et al. Bone acquisition in healthy children and adolescents: comparisons of dual x-ray absorptiometry and computed tomography measures. J Clin Endocrinol Metab 2005; 90:1925-1928. A comparison of DXA versus CT suggests that bone mineral content rather than bone mineral density may be a more precise reflection of bone status in children.
25. Haugeberg G, Orstavik RE, UhligT, et al. Comparison of ultrasound and X-ray absorptiometry bone measurements in a case control study of female rheumatoid arthritis patients and randomly selected subjects in the population. Osteoporos Int 2003; 14:312-319.
26. Orstavik RE, Haugeberg G, Uhlig T, et al. Quantitative ultrasound and bone mineral density: discriminatory ability in patients with rheumatoid arthritis and controls with and without vertebral deformities. Ann Rheum Dis 2004; 63:945-951.
27. Falcini F, Bindi G, ERmini M, et al. Comparison of quantitative calcaneal ultrasound and dual energy x-ray absorptiometry in the evaluation of osteoporotic risk in children with chronic rheumatic disease. Calcif Tissue Int 2000; 67:19-23.
28. Hartman C, Shamir R, Eshach-Adiv O, et al. Assessment of osteoporosis by quantitative ultrasound versus dual energy x-ray absorptiometry in children with chronic rheumatic disease. J Rheumatol 2004; 31:981-985. This interesting study in children with rheumatic disease found equivalent bone mineral density assessment by QUS compared to DXA.
29. Fricke O, Tutlewski B, Schwahn B, Schoenau E. Speed of sound:relation to geometric characteristics of bone in children, adolescents, and adults. J Pediatr 2005; 146:764-768.
30. Manolagas SC, Jilka RL Bone marrow, cytokines, and bone remodeling. N Engl J Med 1995; 332:305-311.
31. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96:3540-3545.
32. Anderson MA, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390:175-179.
33. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
34. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is the ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-3602.
35. Wong BR, Rho J, Aaron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. J Biol Chem 1997; 272:25190-25194.
36. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclasts differentiation factor and macrophage-colony stimulating factor is sufficent for both human and mouse osteoclasts formation in vitro. Endocrinology 1998; 139:4424-4427.
37. Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Com 1998; 246:199-204.
38. Fuller K, Wong B, Fox S, et al. TRANCE is necessary and sufficient for osteoblasts-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188:997-1001.
39. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
40. Yasadu H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 38: 1329-1337.
41. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12.
42. Masi L, Simonini G, Piscitelli E. et al. Osteoprotegerine (OPG)/RANKL-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? J Rheumatol 2004; 31:986-991. The first report of RANKL and OPG in children with JIA describes increased OPG/RANKL compared to controls.
43. Arai K, Lee F, Miyajima A, et al. Cytokines: co-ordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59:783-836.
44. Berghe WV, Vermeulen L, DeWilde G, et al. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 2000; 60:1185-1195.
45. Thomson BM, Mundy GR, Chamber TJ. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987; 138:775-779.
46. Wei S, Kitaura H, Zhou P, et al. IL-1 mediatres TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282-290. This innovative research proposes a link between IL-1, TNF, and RANKL. The pathogenesis of osteoclastogenesis is potentially broadened.
47. Jimi E, Nakamura I, Duong LT, et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999; 247:84-93.
48. Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatol 2004; 43:10-16. Further evidence of IL-1 in the role of bone resorption is suggested in this study.
49. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIH Concensus Statement 2000; 17:1-36.
50. Bonjour JP, Carrie AL, Ferrari S, et al. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo controlled trial. J Clin Invest 1997; 99:1287-1294.
51. Lehtonen-Veromaa MKM, Mottonen TT, Nuotio IO, et al. Vitamin D and attainment of peak bone mass among perpubertal Finnish girls: a 3-year prospective study. Am J Clin Nutr 2002; 76:1446-1453.
52. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficeincy in postmenopausal US women with acute hip fracture. JAMA 1999; 281:1505-1511.
53. Boonen S, Vanderschueren D, Cheng XG, et al. Age-related (type II) femoral neck osteoporosis in men: biochemical evidence for both hypovitaminiosis D- and androgen deficiency-induced bone resorption. J Bone Miner Res 1997; 12:2119-2126.
54. National Institutes of Health. Optimal calcium intake. NIH Concensus Statement 1994; 12:1-31.
55. Institute of Medicine. Dietary Reference Intakes for Calcium Phosphorus, Magnesium, Vitamin D and Fluoride. 1997 National Academy Press Washington, DC.
56. Kohrt WM, Bloomfield SA, Little KD, et al. American College of Sports Medicine Position Stand: physical activity and bone health. Med Sci Sports Exerc 2004; 36:1985-1996. An excellent summary of literature emphasizing the importance of weight-bearing exercise to promote bone health in childhood as well as into adulthood.
57. Valimaki MJ, Karkkainen M, Lamberg-Allardt C, et al. Exercise, smoking, and calcium intake during adolescence and early adulthood as determinants of peak bone mass. BMJ 1994; 308:230-235.
58. Van Staa TP, Cooper C, Leukfens HGM, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bon Miner Res 2003; 18: 913-918.
59. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001; 44:1496-1503.
60. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendromate for the treatment of osteoporosis in diffuse connective tissue disease in children: a prospective multicenter study. Arthritis Rheum 2000; 43:1960-1966.
61. Noguera A, Ros JB, Pavia C, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Ped Endo Metab 2003; 16:529-536.
62. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 2003; 142:417-423.
63. El-Husseini AA, El-Agroudy AE, El-Sayed MF, et al. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004; 8:357-361. This study is one of few in pediatrics to prospectively examine bisphosphonates or calcitonin compared to a control group. The children in the treatment arms had improvement in DXA measurements, while bone density decreased in the control group.
64. Canatan D, Akar N, Arcosoy A. Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 1995; 93:20-24.